Erectile dysfunction is a common clinical entity that affects mainly men older than 40 years.
In addition to the classical causes of erectile dysfunction, such as diabetes mellitus and …

The superfamily of cyclic nucleotide (cN) phosphodiesterases (PDEs) is comprised of 11
families of enzymes. PDEs break down cAMP and/or cGMP and are major determinants of …

Introduction Erectile dysfunction (ED) is a major complication of type 2 diabetes, and many
diabetic men with ED are refractory to common ED therapies. Aim To determine whether …

The treatment for erectile dysfunction (ED) was revolutionized with the development of
phosphodiesterase type 5 (PDE5) inhibitors. Tadalafil (Cialis®; Eli Lilly and Company …

Tadalafil is a phosphodiesterase-5 inhibitor that is characterized by low solubility and high
permeability. Solid dispersion approach represents a promising carrier system for effective …

Introduction Dyslipidemia is closely related to erectile dysfunction (ED). Evidence has shown
that the lipid‐lowering agent, 3‐hydroxy‐3‐methylglutaryl‐coenzyme A reductase inhibitor …

Objective: To evaluate the efficacy and safety of tadalafil monotherapy for lower urinary tract
symptoms secondary to benign prostatic hyperplasia (LUTS/BPH). Methods: A …

There has been increasing interest in the use of PDE5 inhibitors to treat BPH/LUTS.
Combination of PDE5 inhibitors and α1-adrenergic blockers may have an additive beneficial …

Phosphodiesterase 5 (PDE5) inhibitors presented themselves as important players in the
nitric oxide/cGMP pathway, thus exerting a profound impact on various physiological and …

Abstract PDE5 inhibitors (PDE5i) are widely known as treatment for erectile dysfunction
(ED). This favorable action has emerged as a “side effect” from pioneering studies when …